Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 26, 2018

View Archived Issues

FDA grants orphan drug designation to GDC-0084 for glioblastoma multiforme

EC first to approve Crysvita for treatment of X-linked hypophosphatemia

CHMP adopts positive opinion for Lynparza tablets in platinum-sensitive relapsed ovarian cancer

Orencia approved for active polyarticular JIA in Japan

First patient enrolled in phase II study of defibrotide for acute GvHD

Provectus updates progress of PV-10 GI cancer program

Prevymis launched in Germany

EMA committee recommends against expanding use of Sutent in adults at high risk of recurrent RCC

FDA accepts Mallinckrodt's NDA for stannsoporfin

University of South Florida patents reelin compounds for neurodegeneration

EMA committee hands down negative opinion on Puma's neratinib

Takeda divulges new ROR-gammaT modulators for cancer

Bellicum Pharmaceuticals gives update on FDA clinical hold on BPX-501

InnoCare Pharma identifies novel FGFR inhibitors

Toray Industries discovers microRNA-4454-targeting antisense polynucloetides

New mouse model points to TGF-beta signaling in metastatic colorectal cancers

Xgeva recommended for E.U. approval to prevent skeletal-related events in multiple myeloma

Novel GCN2 inhibitors presented by Takeda

FDA approves Apadaz for short-term management of acute pain

EMA committee hands down positive opinion for Kineret in Still's disease

EMA committee recommends approval of Mylotarg and Bosulif in E.U.

NOP agonist AT-312 can reduce alcohol reward

University of Liverpool leads project to develop Zika virus vaccine suitable for use in pregnancy

Researchers detail development and antitumor activity of MK-8353 in patients with solid tumors

Amglidia recommended for E.U. approval for neonatal diabetes

BioCryst's Alpivab recommended for approval in E.U. for uncomplicated influenza

ARS-1620 is a potent and selective new compound targeting p.G12C KRAS mutant cancers

EMA committee recommends change to marketing authorization terms for Feraccru

FDA agrees to waive pediatric trials for Luye's LY-03004

We want your opinion - complete our user survey